comparemela.com

Page 4 - Uc Davis Health News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Elafibranor has significant, sustained treatment benefit in PBC through 78 weeks

Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.“There is a major unmet need for a primary biliary cholangitis (PBC) treatment that effectively targets the biochemical indicators of disease

Common anti-inflammatory drug could combat deadly gut fungus, study finds

A team of UC Davis Health researchers discovered that a common anti-inflammatory drug, mesalamine, can replace the work of good bacteria in fighting the nasty fungus Candida albicans in the gut.

Autism Risk Increases in Children With Autistic Relatives

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.